General MedicationsINTRAVENOUSGeneric
IOBENGUANE I-123
IOBENGUANE SULFATE I-123
Standard Dose
10mCi/5ML (2mCi/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview IOBENGUANE I-123 is listed in Drugs@FDA under application 213637 (ANDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient IOBENGUANE SULFATE I-123 Form and strength SOLUTION;INTRAVENOUS - 10mCi/5ML (2mCi/ML) Sponsor BWXT MEDCL Submission history Latest submission status date: 2024-12-09 00:00:00.
Structured Monograph
Clinical summary
Approval overview IOBENGUANE I-123 is listed in Drugs@FDA under application 213637 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient IOBENGUANE SULFATE I-123 Form and strength SOLUTION;INTRAVENOUS - 10mCi/5ML (2mCi/ML) Sponsor BWXT MEDCL Submission history Latest submission status date: 2024-12-09 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.